Pipeline
Our lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.
We are also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets.
Our AI-led discovery programmes leverage data from over 20 years of human challenge trials and have identified clinically relevant drug targets and treatments. AI-led solutions potentially enable faster target identification, at lower cost, reduced risk, and potentially increased likelihood of success.
Learn more
